This study is a registry gathering information on how a procedure called Blue Light Cystoscopy with Cysview (BLCC) is used in doctors' offices for bladder cancer. BLCC uses a drug called hexaminolevulinate hydrochloride (HCL) and a special camera system (Karl Storz D-Light C Photodynamic Diagnostic (PDD) system) to help doctors see bladder tumors better. The study wants to understand if BLCC helps find more bladder cancers than standard methods, how different tumor features affect this, and how it performs in specific situations. We are looking for adults over 18 who have suspected or known non-muscle invasive bladder cancer. You cannot join if you have porphyria, significant blood in your urine, or are allergic to hexaminolevulinate or similar drugs. The main goal is to see how well BLCC detects bladder cancers over five years.

Study design

This is an observational study, meaning researchers will collect information about how Blue Light Cystoscopy with Cysview is currently used in practice. It plans to include about 4400 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will track the rate of bladder cancer detection for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.